HER2-Targeted Regimen Achieves 60.2% Pathologic Complete Response Rate in Locally Advanced HER2-Positive Breast Cancer in China’s Phase II neoPICD Trial, Presented at ASCO Breakthrough 2026

August 9, 2026

The ASCO Post USA

Overview

A HER2-targeted regimen demonstrated a high pathologic complete response (pCR) rate of 60.2% in patients with locally advanced HER2-positive breast cancer in the phase II neoPICD trial conducted in China. Presented at the 2026 ASCO Breakthrough Meeting, the study enrolled 124 patients, showing more pronounced responses in hormone receptor-negative tumors. These results highlight a significant therapeutic advance, potentially offering a new effective neoadjuvant option for this patient population.

In Depth

Key Findings

A HER2-targeted regimen achieved a high pathologic complete response (pCR) rate of 60.2% in patients with locally advanced HER2-positive breast cancer, as reported from the phase II neoPICD trial at the 2026 ASCO Breakthrough Meeting.

Technical / Clinical Details

The neoPICD trial, conducted in China, enrolled 124 patients diagnosed with locally advanced HER2-positive breast cancer. Following treatment with the HER2-targeted regimen, the observed pCR rate—indicating the complete absence of invasive cancer in the breast and axillary lymph nodes—was 60.2%. This robust response rate is particularly noteworthy. Further analysis revealed that responses were even more pronounced in patients with hormone receptor (HR)-negative tumors, suggesting that HR status might serve as a predictive biomarker for treatment efficacy within this regimen. The findings underscore the potential of this HER2-targeted approach to significantly improve outcomes in the neoadjuvant setting for this aggressive subtype of breast cancer.

Background & Context

HER2-positive breast cancer is characterized by aggressive biology and a higher propensity for recurrence, historically demanding intensified treatment strategies. While advancements in HER2-targeted therapies have substantially improved patient prognosis, the quest for highly effective neoadjuvant regimens capable of achieving deep and durable responses remains a critical area of research. Pathologic complete response is a well-established surrogate endpoint for long-term survival outcomes in early and locally advanced breast cancer, with patients achieving pCR often experiencing superior event-free and overall survival rates compared to those who do not. A pCR rate exceeding 60% represents a substantial clinical improvement over historical benchmarks.

Strategic Significance & Outlook

The encouraging results from the neoPICD trial suggest that this HER2-targeted regimen could emerge as a new standard of care for neoadjuvant treatment in locally advanced HER2-positive breast cancer. The differential response observed in HR-negative tumors also opens avenues for refined patient selection and personalized therapeutic strategies. Future investigations will likely focus on larger, randomized Phase III trials to confirm these promising pCR rates and to evaluate long-term outcomes, including disease-free survival (DFS) and overall survival (OS). This advancement has the potential to significantly improve the treatment landscape and prognosis for patients with HER2-positive breast cancer globally.

Source: https://ascopost.com/news/august-2026/her2-targeted-regimen-yields-high-pathologic-complete-response-rate-in-locally-advanced-breast-cancer/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.